X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

WHO Puts In Place Another Training Hub For Biomanufacturing

Content Team by Content Team
26th February 2022
in News
WHO Puts In Place Another Training Hub For Biomanufacturing

WHO along with its academy and the Republic of Korea, have announced the inception of a global bio manufacturing training hub that will be of assistance to low and mid-income countries who are inclined to develop biologicals ranging from vaccines and insulin to cancer treatments and monoclonal antibodies.

The establishment comes after a global mRNA vaccine tech transfer hub was setup in South Africa. As per WHO’s DG, Dr. Tedros Adhanom Ghebreyesus, one of the many barriers when it comes to successful tech transfer in low and middle-income countries is the lack of skilled manpower and also regulatory norms that are pretty weak. By building the required skills, these countries will ensure that they are able to develop high-quality standard products that they need and, thereby, will not have to wait for their turn at the end of the queue, as is usually the case.

It is well to be taken into account that the government of the Republic of Korea has come up with a large facility outside the capital of Seoul which has already begun to carry out biomanufacturing training for companies based within the country. They now intend to train trainees from other countries in their facility, which will provide technical as well as hands-on support for operational and GMP requirements.This will be in line with the exclusive training developed by the mRNA vaccine technology hub based in South Africa.

Kwon Deol-cheol, Health and Welfare Minister of South Korea, states that 60 years ago, Korea was regarded as one of the poorest countries in the world, but with the guidance of WHO and the international community, they have transformed into a country with a robust public health system as well as a bio industry.

Because of their own experiences from the past, today they strive to support countries that are poor and ensure that their bio manufacturing is strengthened so that a safer place can be created during a future pandemic. WHO is also in the midst of intensifying the regulatory system through its global benchmarking tool, which is a yardstick that gauges the maturity level of regulatory authorities. This tool would serve as the most pivotal parameter when it comes to the WHO authorities list.

Significantly, five countries—Pakistan, Serbia, Bangladesh, Vietnam, and Indonesia—will receive all the support from South Africa’s global mRNA hub. With targeted training, the mentioned countries were vetted by experts and also established the fact that they had what was required for tech absorption. With this training, they will be able to swiftly move towards the production stage.

As per Retno Lestari Priansari Marsudi, Foreign Affairs Minister, Indonesia, their country happens to be one of those that has always supported equal access to COVID-19 vaccines in all the territories by way of transfer of vaccine technology to underdeveloped economies.

Dr. Zlatibor Loncar, Serbian Health Minister, says that the development of new technology will pave the way for the professional knowledge of Serbian experts, which, according to him, is a national priority. Vietnam’s Health Minister, Dr. Nguyen Thanh Long, says that being a developing country, Vietnam has a fair amount of experience in vaccine development when it comes to the past few decades. By participating in this initiative, mRNA vaccines will be produced on a large scale in their country, not only for domestic consumption but for other countries in the world, which will help in the eradication of inequalities in vaccine access.

It is well to be noted that Brazil and Argentina were the first countries from the Americas to join this initiative and get the mRNA tech from the global hub. Companies from both these countries have since then received apt training from the hub.

Previous Post

MNC Pharmaceutical Giants Restructure Their India Presence

Next Post

Is Pancorona Virus Vaccine Possible? Dr. Weissman Says So

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use

Is Pancorona Virus Vaccine Possible? Dr. Weissman Says So

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In